Janet Woodcock’s imminent departure from the agency has been predicted often during her tenure. Her latest project may keep her there longer than even she thought possible.
Many predictions have been made about Janet Woodcock’s retirement from the US Food and Drug Administration: when she celebrated 30 years at the agency, when she left the drug center to join the Trump Administration’s Operation Warp Speed, and most recently, when she was passed over by the Biden Administration as the permanent commissioner for Robert Califf.
Surely, after nearly a year at the top spot at the FDA, even on an acting basis, Woodcock would hang...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
